A
A. Stähle
Publications - 15
Citations - 3023
A. Stähle is an academic researcher. The author has contributed to research in topics: Carboplatin & Ovarian cancer. The author has an hindex of 11, co-authored 15 publications receiving 2667 citations.
Papers
More filters
Journal ArticleDOI
A phase 3 trial of bevacizumab in ovarian cancer.
Timothy J. Perren,Ann Marie Swart,Jacobus Pfisterer,Jonathan A. Ledermann,Eric Pujade-Lauraine,Gunnar B. Kristensen,Mark S. Carey,Philip Beale,Andrés Cervantes,Christian Kurzeder,Andreas du Bois,Jalid Sehouli,Rainer Kimmig,A. Stähle,Fiona Collinson,Sharadah Essapen,Charlie Gourley,Alain Lortholary,Frédéric Selle,Mansoor Raza Mirza,Arto Leminen,Marie Plante,Dan Stark,Wendi Qian,Wendi Qian,Mahesh K. B. Parmar,Amit M. Oza,Icon investigators +27 more
TL;DR: In patients at high risk for progression, the benefit was greater with bevacizumab than without it, with progression-free survival (restricted mean) at 42 months of 14.5 months, higher than the average for women with ovarian cancer.
Journal ArticleDOI
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
Jacobus Pfisterer,Marie Plante,Ignace Vergote,Andreas du Bois,Hal W. Hirte,A. J. Lacave,Uwe Wagner,A. Stähle,Gavin Stuart,Rainer Kimmig,S. Olbricht,Tien Le,Janusz Emerich,Walther Kuhn,James Bentley,Christian Jackisch,Hans-Joachim Lück,Justine Rochon,Annamaria Zimmermann,Elizabeth Eisenhauer +19 more
TL;DR: Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
Journal ArticleDOI
Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO
Jacobus Pfisterer,Béatrice Weber,Alexander Reuss,Rainer Kimmig,Andreas du Bois,Uwe Wagner,Hugues Bourgeois,Werner Meier,SD Costa,Jens-Uwe Blohmer,Alain Lortholary,S. Olbricht,A. Stähle,Christian Jackisch,Anne-Claire Hardy-Bessard,Volker Möbus,Jens Quaas,Barbara Richter,W. Schröder,Jean-François Geay,Hans-Joachim Lück,Walther Kuhn,Harald Meden,Ulrike Nitz,Eric Pujade-Lauraine,Gineco +25 more
TL;DR: The sequential addition of topotecan to carboplatin-paclitaxel did not result in superior overall response or progression-free or overall survival, and this regimen is not recommended as standard of care treatment for ovarian cancer.
Journal ArticleDOI
Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6).
Uwe Wagner,Andreas du Bois,Jacobus Pfisterer,Jens Huober,S. Loibl,Hans-Joachim Lück,Jalid Sehouli,Martina Gropp,A. Stähle,Barbara Schmalfeldt,Werner Meier,Christian Jackisch +11 more
TL;DR: Gefitinib plus tamoxifen did not appear to be efficacious in the treatment of patients with refractory/resistant ovarian cancer, and the addition of tamoxIFendid not worsen the known side effects of gefit inib, or induce additional side effects.
Journal ArticleDOI
Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group.
Felix Hilpert,A. Stähle,O. Tome,Alexander Burges,D. Rossner,K. Späthe,V. Heilmann,Barbara Richter,A. du Bois +8 more
TL;DR: Amifostine improved sensory neuropathy according to NCI-CTC and with regard to objective neurological assessment, but there were almost no differences in self-estimated specific sensory or motor symptoms.